Ligand Pharmaceuticals Incorporated
LGND
$159.40
$0.610.38%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.06% | 5.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.06% | 5.89% | |||
| Cost of Revenue | -82.75% | 656.46% | |||
| Gross Profit | 497.39% | -127.01% | |||
| SG&A Expenses | 7.31% | -26.57% | |||
| Depreciation & Amortization | 0.01% | -0.01% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -53.77% | 99.37% | |||
| Operating Income | 126.51% | -2,273.03% | |||
| Income Before Tax | 122.37% | -28.01% | |||
| Income Tax Expenses | 182.49% | 4.72% | |||
| Earnings from Continuing Operations | 111.42% | -36.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 111.42% | -36.55% | |||
| EBIT | 126.51% | -2,273.03% | |||
| EBITDA | 162.84% | -374.87% | |||
| EPS Basic | 111.34% | -35.00% | |||
| Normalized Basic EPS | 127.01% | -356.40% | |||
| EPS Diluted | 110.85% | -34.77% | |||
| Normalized Diluted EPS | 126.20% | -356.40% | |||
| Average Basic Shares Outstanding | 0.71% | 1.14% | |||
| Average Diluted Shares Outstanding | 3.83% | 1.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||